Federal Trade Commission

Market Access
pharmaphorum podcast episode 115

The 2024 biopharma M&A landscape: An overview

It’s been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats.

Market Access
King chess piece

Illumina-Grail saga ends with divestment

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commiss